Given the increase in resistance to antibacterial agents, there is an urgent need for the development of new agents with novel modes of action. As an interim solution, it is also prudent to reinvestigate old or abandoned antibacterial compounds to assess their efficacy in the context of widespread resistance to conventional agents. In the 1970s, much work was performed on the development of peptide mimetics, exemplified by the phosphonopeptide, alafosfalin. We investigated the activity of alafosfalin, di-alanyl fosfalin and β-chloro-L-alanyl-β-chloro-L-alanine against 297 bacterial isolates, including carbapenemase-producing Enterobacterales (CPE) (n = 128), methicillin-resistant Staphylococcus aureus (MRSA) (n = 37) and glycopeptide-resistant enterococci (GRE) (n = 43). The interaction of alafosfalin with meropenem was also examined against 20 isolates of CPE. The MIC50 and MIC90 of alafosfalin for CPE were 1 mg/L and 4 mg/L, respectively and alafosfalin acted synergistically when combined with meropenem against 16 of 20 isolates of CPE. Di-alanyl fosfalin showed potent activity against glycopeptide-resistant isolates of Enterococcus faecalis (MIC90; 0.5 mg/L) and Enterococcus faecium (MIC90; 2 mg/L). Alafosfalin was only moderately active against MRSA (MIC90; 8 mg/L), whereas β-chloro-L-alanyl-β-chloro-L-alanine was slightly more active (MIC90; 4 mg/L). This study shows that phosphonopeptides, including alafosfalin, may have a therapeutic role to play in an era of increasing antibacterial resistance.
Pseudomonas aeruginosa is a dominant cause of respiratory infection in individuals with cystic fibrosis (CF), leading to significant morbidity and mortality. Detection of P. aeruginosa is conducted by culture of respiratory samples but this process may occasionally be compromised due to overgrowth by other bacteria and fungi. We aimed to evaluate a novel chromogenic medium, Pseudomonas aeruginosa chromogenic agar (PACA), for culture of P. aeruginosa from respiratory samples, from patients with CF. A total of 198 respiratory samples were cultured onto PACA and three other media: CHROMID® P. aeruginosa, CHROMagar™ Pseudomonas and MacConkey agar. P. aeruginosa was recovered from 66 samples (33%), using a combination of all media. After 72 h incubation, the sensitivity of the four chromogenic media was as follows: 91% for PACA and CHROMagar™ Pseudomonas, 85% for CHROMID® P. aeruginosa and 83% for MacConkey agar. For the three chromogenic media, the positive predictive value after 72 h was as follows: 95% for PACA, 56% for CHROMagar™ Pseudomonas and 86% for CHROMID® P. aeruginosa. PACA proved to be a highly effective culture medium for the isolation and specific detection of P. aeruginosa from respiratory samples.
In clinical culture media inoculated with patient samples, selective inhibition of commensal bacteria is essential for accurate diagnosis and effective treatment, as they can mask the presence of pathogenic bacteria. The alanine analogue, 1-aminoethyltetrazole was investigated as a potential alanine racemase inhibitor. For effective uptake and enhanced and selective antibacterial activity, a library of C-terminal 1-aminoethyltetrazole containing di- and oligopeptides were synthesized by solid phase peptide coupling techniques. The investigation of the antimicrobial activity of the synthesised compounds identified several clinically applicable selective inhibitors. These enabled differentiation between the closely related bacteria, Salmonella and Escherichia coli, which can be difficult to discriminate between in a clinical setting. In addition, differentiation between enterococci and other Gram-positive cocci was also seen.
Accurate label claims are essential for consumer trust in probiotic efficacy, yet limited datasets are available for poultry formulations marketed in the United Kingdom. We quantified and identified the viable bacteria in twelve commercial probiotics, seven for poultry and five for human use, using selective plate counts and MALDI-TOF MS. Observed colony forming units (CFU) were compared with declared values using one-sample t-tests, adopting a practical acceptance range of ±0.5 log CFU. Poultry products largely met or exceeded their labels (e.g., P5: 1.4 × 1010 CFU g−1 vs. 2 × 109 CFU g−1 declared), whereas human products delivered greater variability in both species composition and stated CFU count; one contained no detectable viable bacteria. All products deviated significantly from their label claims (p < 0.05); however, 11 of 12 met the ±0.5 log10 CFU benchmark—10 within the range and 1 above its “≥” value—leaving only one probiotic below the threshold. MALDI-TOF MS confirmed the presence of most labelled species, though Bifidobacterium bifidum was absent from one human product and Bacillus isolates were re-assigned to B. velezensis/B. amyloliquefaciens. These findings indicate robust quality assurance in UK poultry probiotics, but substantial under-delivery in the human probiotics, underscoring the need for harmonized viability standards and tighter post-market surveillance.
In diagnostic microbiology, culture media are widely used for detection of pathogenic bacteria. Such media employ various ingredients to optimize detection of specific pathogens such as chromogenic enzyme substrates and selective inhibitors to reduce the presence of commensal bacteria. Despite this, it is rarely possible to inhibit the growth of all commensal bacteria, and thus pathogens can be overgrown and remain undetected. One approach to attempt to remedy this is the use of “suicide substrates” that can target specific bacterial enzymes and selectively inhibit unwanted bacterial species. With the purpose of identifying novel selective inhibitors, six novel phosphonopeptide derivatives based on d/l-fosfalin and β-chloro-l-alanine were synthesized and tested on 19 different strains of clinically relevant bacteria. Several compounds show potential as useful selective agents that could be exploited in the recovery of several bacterial pathogens including Salmonella, Pseudomonas aeruginosa, and Listeria.
Background: Prompt administration of optimal antibiotic therapy is essential in the management of bacteraemia to reduce morbidity and mortality and to facilitate antibiotic stewardship. To identify the most effective therapy, rapid and accurate antimicrobial susceptibility testing (AST) is essential. ASTar is an automated AST system that delivers minimum inhibitory concentrations (MICs) for 23 antimicrobials and is designed for testing Gram-negative bacteria directly from positive blood cultures, with results available after 6 h. Methods: The ASTar system was evaluated with 64 positive blood cultures from patients with bacteraemia and 56 simulated blood cultures inoculated with a range of antibiotic-resistant isolates. The ASTar results for 12 antibiotics commonly used in our hospitals were compared with the results derived from three different methods of disc susceptibility testing and MICs determined by broth microdilution (BMD). Results: For 121 isolates of Gram-negative bacteria, ASTar showed an average essential agreement of 87.2% and an average categorical agreement of 94%, when compared with BMD. Very major errors (false susceptibility) and major errors (false resistance) were associated with 0.9% and 3.4% of results, respectively. The results were at least as accurate as those obtained from EUCAST disc susceptibility methods (both rapid and overnight methods). Conclusions: The ASTar system is an effective method for delivering accurate and rapid (6 h) AST results for Gram-negative bacteria by the direct testing of positive blood cultures.